Clinical Trials Logo
  1. Home
  2. Pure Red Cell Aplasia
  3. NCT01362595

Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia — LeucineDBA  

Diamond Blackfan Anemia Clinical Trial

Official title:
The Use of Novel Therapies to Reconstitute Blood Cell Production and Promote Organ Performance Using Bone Marrow Failure as a Model: a Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia

Clinical Trial Summary

This study will determine the safety and possibility of giving the amino acid, leucine, in patients with Diamond Blackfan anemia(DBA)who are on dependent on red blood cell transfusions. The leucine is expected to produce a response in patients with DBA to the point where red blood cell production is increased. Red cell transfusions can then be less frequent or possibly discontinued. The investigators will study the side effects, if any, of giving leucine to DBA patients. Leucine levels of leucine will be obtained at baseline and during the study. The drug leucine will be provided in capsule form and taken 3 times a day for a total of 9 months.

Clinical Trial Description

Leucine will be provided to participants in the form of a capsule and will be taken three times daily. Blood hemoglobin levels will be monitored every 3-4 weeks for 9 months. The entire study will last 12-15 months in length. Subjects must be two years of age or older and on transfusion for more than six months prior to enrollment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01362595
Study type Interventional
Source Northwell Health
Contact
Status Completed
Phase Phase 1/Phase 2
Start date June 2013
Completion date November 30, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02386267 - L-leucine in Diamond Blackfan Anemia Patients Phase 2
Recruiting NCT02179359 - Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies N/A
Terminated NCT03966053 - The Use of Trifluoperazine in Transfusion Dependent DBA Phase 1/Phase 2
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT00235391 - Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Phase 3
Recruiting NCT00027274 - Cancer in Inherited Bone Marrow Failure Syndromes
Recruiting NCT01758042 - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders N/A
Terminated NCT00001962 - A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure Phase 2
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Terminated NCT03733249 - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Phase 1/Phase 2
Terminated NCT01464164 - Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia Phase 1/Phase 2
Completed NCT00011505 - Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia Phase 2
Terminated NCT02065869 - Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant Phase 1/Phase 2
Recruiting NCT04099966 - AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion Phase 2